Informations

Acute Myeloid Leukemia (AML), as a highly heterogeneous malignancy, presents immense challenges to precise clinical subtyping and treatment due to its complex biological characteristics. Although existing clinical guidelines, such as…

The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on “Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy.” She systematically…

Precision Diagnosis and Risk Stratification: The Cornerstone of Individualized Treatment The new EHA guidelines first emphasize the central role of precise diagnosis and comprehensive risk assessment in the management of…

In the high summer of 2025, the highly anticipated European Hematology Association (EHA) Annual Meeting was convened, bringing together top global experts in hematologic oncology to discuss cutting-edge progress and future directions in the field. In the Chronic Lymphocytic Leukemia (CLL) session, Dr. Daisy Diaz, a postdoctoral fellow from MD Anderson Cancer Center in the…

As a scholar with a research career spanning over 30 years, Professor Alberto Orfao began his lecture by expressing his profound gratitude. He attributed this honor to the hundreds of…

Acute myeloid leukemia, subtype M2b (AML-M2b), was first identified in 1959 by Professor Chongli Yang at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), based on clinical features, bone marrow morphology, and cytology. He termed it “subacute granulocytic leukemia.” In 1973, Rowley and colleagues abroad reported the same leukemia…